It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Novo Nordisk on Wednesday announced an expanded deal with healthtech firm Valo Health to use AI to fuel drug discovery.
By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals’ dominance in the GLP-1 space.
Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
A new study suggests increasingly popular GLP-1 drugs could help cut opioid and alcohol abuse nearly in half.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
WW announced on Thursday that it will be laying off employees and cutting costs to the tune of $100 million per year.
Novo Nordisk scored approval to sell its Wegovy weight loss drug in China. That’s a big win, but competitors will soon flood in.
A loophole lets the company create a back-door offering of a generic drug before the patents of Novo Nordisk and Eli Lilly expire.
The regulator sees some patents as ploys to keep companies from developing cheaper generic versions of 20 different brand-name drugs.
A new survey finds evidence that “the drugs have a meaningful impact on consumer behavior and spending on groceries and restaurants.”
A GLP-1 medication from French drugmaker Sanofi — similar to Ozempic — was found to slow Parkinson’s in a small mid-stage trial.
The partnership is going nationwide after a successful run at 160 McDonald’s locations across Kentucky.
Facebook and other social media platforms are the subject of a probe by federal prosecutors into available medications.
The company, now one of Europe’s biggest, is trying to keep supply up with still-astronomical demand.